About 100,000 of the estimated million people in the United States with multiple sclerosis (MS) have a progressive form of ...

Scientists have identified an unusual type of brain cell that may play a vital role in progressive multiple sclerosis (MS), likely contributing to the persistent inflammation characteristic of the ...

Zenas Biopharma has acquired global rights to develop BTK inhibitor orelabrutinib to treat progressive forms of multiple ...

The CAR T-cell therapy equecabtagene autoleucel, or eque-cel, was shown in trial to improve walking ability for five ...

A multicenter phase 3 trial comparing ocrelizumab to fingolimod for children with MS achieved its noninferiority primary ...

Scientists have identified an unusual type of brain cell that may play a vital role in progressive multiple sclerosis (MS), ...

Researchers have identified a rare type of brain cell that may drive the chronic inflammation and neurodegeneration seen in progressive multiple sclerosis (MS).

The FDA has extended the review period of the New Drug Application for tolebrutinib for the treatment of non-relapsing, secondary progressive MS and to slow disability accumulation independent of ...

SAN DIEGO -- Investigational tolebrutinib slowed disability progression in people with non-relapsing secondary progressive multiple sclerosis (SPMS), the phase III HERCULES trial showed. The Bruton's ...

Cambridge scientists say they are “on the brink of a new class of treatments” to stop the progression of multiple sclerosis ...

Multiple sclerosis (MS) is an inflammatory condition that damages the myelin of the central nervous system, leading to neurologic impairment and possibly severe disability. MS is characterized by ...

In relapse-remitting multiple sclerosis (MS), people experience periods of high MS activity where they have more symptoms or imaging tests show inflammation. Between these periods, the condition might ...